What is the 13F Pro Quality Score for GRAL?

13F Pro ranks GRAIL, Inc. (GRAL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GRAL's current score at https://13fpro.ai/research/GRAL (free sign-up required for the full ranking).

Which hedge funds own the most GRAL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GRAL include BAKER BROS. ADVISORS, FARALLON CAPITAL MANAGEMENT, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/GRAL as soon as new 13F filings post.

Where does 13F Pro source GRAL data?

All GRAIL, Inc. fundamentals and ownership data come directly from SEC EDGAR. GRAIL, Inc. files with the SEC under CIK 1699031. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GRAL in?

GRAIL, Inc. (GRAL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GRAL research updated on 13F Pro?

GRAL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GRAIL, Inc.(GRAL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1699031 GRAL stock profile & AI dashboard →

13F Pro Quality Score

31.9/100

Rank #2,296 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

92.3/100

Profitability

4.6/100

Balance Sheet

14.6/100

Earnings Quality

30.0/100

Free Cash Flow

4.8/100

Institutional Flow

94.7/100

Revenue Scale

20.7/100

Dilution Risk

5.3/100

GRAL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GRAIL, Inc. (GRAL), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GRAL at 31.9/100 on a 32-signal composite quality model, placing it at rank #2,296 of 2,879 stocks — the bottom half of the AI-ranked universe. GRAL scores in the top quartile across institutional flow (94.7), revenue growth (92.3). Areas of concern include profitability (4.6) and free cash flow (4.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 5.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), GRAIL, Inc. reports quarterly revenue of $40.8M, net income of $-93.2M, free cash flow of $-87.5M. Top institutional holders of GRAL by reported 13-F value include BAKER BROS. ADVISORS, FARALLON CAPITAL MANAGEMENT, BlackRock,, based on the most recent SEC filings. GRAL trades on the Nasdaq exchange and files with the SEC under CIK 1699031. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GRAL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GRAIL, Inc. directly from SEC EDGAR. GRAIL, Inc.'s 13F Pro composite quality score has ranged between 8 and 84 since 2025, currently 31.9 — an improving long-term trajectory across 40 quarterly and live scoring snapshots.

✦

Fun facts about GRAIL, Inc.

Quirks, history, and lore behind GRAL — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
The company has burned through hundreds of millions of dollars in pursuit of its mission, with revenue still in early-stage territory — this is a pre-profitability biotech betting big on a moonshot.
3
The History
Founded around 2016 and backed early by Illumina, the genomics giant that later tried — and ultimately failed — to fully absorb it after a prolonged antitrust battle.
4
The Secret
Its core product is a blood test designed to detect multiple cancers at once from a single draw — no biopsy, no symptoms required.
5
The Lore
Its flagship test, Galleri, can screen for more than 50 types of cancer using cell-free DNA signals — the kind of early-detection ambition that makes oncologists and investors equally nervous and excited.
6
The Giveaway
One blood draw. Fifty-plus cancers. A company whose very name evokes the Holy Grail of oncology — catching cancer before you even know it's there.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$40.8M

Net Income

Q1 2026

$-93.2M

Free Cash Flow

Q1 2026

$-87.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+17.2% YoY

$147.2MFY 2025

FY22 $55.5MFY23 $93.1MFY24 $125.6MFY25 $147.2M

Net Income

+79.9% YoY

$-408.4MFY 2025

FY22 $-5.40BFY23 $-1.47BFY24 $-2.03BFY25 $-408.4M

Operating Income

+74.3% YoY

$-562.2MFY 2025

FY22 $-5.44BFY23 $-1.52BFY24 $-2.19BFY25 $-562.2M

EPS (Diluted)

+82.5% YoY

$-11.11FY 2025

FY22 $-173.89FY23 $-47.21FY24 $-63.54FY25 $-11.11

Total Assets

-2.1% YoY

$2.92BFY 2025

FY22 —FY23 $3.91BFY24 $2.98BFY25 $2.92B

Op. Cash Flow

+48.2% YoY

$-299.0MFY 2025

FY22 $-561.3MFY23 $-595.8MFY24 $-577.2MFY25 $-299.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	$147.2M +17.2%	$125.6M +34.9%	$93.1M +67.6%	$55.5M
Net Income	$-408.4M +79.9%	$-2.03B -38.3%	$-1.47B +72.9%	$-5.40B
Operating Income	$-562.2M +74.3%	$-2.19B -44.5%	$-1.52B +72.2%	$-5.44B
EPS (Diluted)	$-11.11 +82.5%	$-63.54 -34.6%	$-47.21 +72.9%	$-173.89
Total Assets	$2.92B -2.1%	$2.98B -23.8%	$3.91B	—
Operating Cash Flow	$-299.0M +48.2%	$-577.2M +3.1%	$-595.8M -6.1%	$-561.3M

AI Insight: GRAL Financial Trends

GRAL remains unprofitable with modest revenue stagnation; operating cash burn has tightened but equity base is shrinking steadily.

• Revenue flat at $36–44M across past five quarters; no growth trajectory evident since Q3 2024.

• Operating cash burn improved from $105M (Q3 2024) to $63–87M range by Q3 2025–Q1 2026.

• Net losses persist at $89–114M per quarter; no path to profitability visible in trailing eight quarters.

⚠ Equity eroded from $2,695M (Q2 2024) to $2,501M (Q1 2026)—7.2% decline over 9 months.

⚠ Operating income losses narrowed Q3 2024 to Q3 2025 ($184M→$125M) but widened again to $136M in Q1 2026.

AI Insight: GRAL Ratio Trends

GRAIL remains deeply unprofitable with negative ROIC averaging -23% across the period, showing no clear path to profitability.

• ROE improved from -19.7% in Q2 2025 to -14.9% in Q1 2026, a 4.8pp recovery but still deeply negative.

• ROIC declined from -19.3% in Q4 2025 to -21.7% in Q1 2026, reversing prior quarter gains.

• ROA range of -13% to -17% across 9 quarters shows persistent asset destruction with no sustained improvement.

⚠ ROIC deteriorated 2.4pp quarter-over-quarter in Q1 2026 after Q4 2025 showed relative strength—monitor for trend reversal.

⚠ Margin data unavailable; cannot assess operating leverage or cash burn trajectory.

Get alerted when GRAL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GRAIL, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GRAL

BAKER BROS. ADVISORS LP
$208.2M4,028,614 sh
FARALLON CAPITAL MANAGEMENT LLC
$168.2M3,253,684 sh
BlackRock, Inc.
$153.4M2,968,536 sh
STATE STREET CORP
$97.8M1,891,893 sh
PRIMECAP MANAGEMENT CO/CA/
$95.3M1,843,772 sh
Deep Track Capital, LP
$89.0M1,722,797 sh
Sessa Capital IM, L.P.
$88.9M1,719,314 sh
MORGAN STANLEY
$84.4M1,632,195 sh
VANGUARD CAPITAL MANAGEMENT LLC
$78.9M1,527,105 sh
Arbiter Partners Capital Management LLC
$53.5M1,034,597 sh

Fund	Value	Shares
BAKER BROS. ADVISORS LP	$208.2M	4,028,614
FARALLON CAPITAL MANAGEMENT LLC	$168.2M	3,253,684
BlackRock, Inc.	$153.4M	2,968,536
STATE STREET CORP	$97.8M	1,891,893
PRIMECAP MANAGEMENT CO/CA/	$95.3M	1,843,772
Deep Track Capital, LP	$89.0M	1,722,797
Sessa Capital IM, L.P.	$88.9M	1,719,314
MORGAN STANLEY	$84.4M	1,632,195
VANGUARD CAPITAL MANAGEMENT LLC	$78.9M	1,527,105
Arbiter Partners Capital Management LLC	$53.5M	1,034,597

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GRAL on your watchlist

Track score changes the day GRAIL, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GRAL a good stock to buy?

13F Pro's AI-powered analysis of GRAIL, Inc. (GRAL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GRAL are available on the GRAL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GRAL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GRAL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GRAIL, Inc.'s investment landscape.